Olivier De Henau

1.9k total citations
22 papers, 609 citations indexed

About

Olivier De Henau is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Olivier De Henau has authored 22 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 10 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in Olivier De Henau's work include Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (6 papers). Olivier De Henau is often cited by papers focused on Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (6 papers). Olivier De Henau collaborates with scholars based in United States, Belgium and France. Olivier De Henau's co-authors include Marc Parmentier, Benjamin Bondue, Patricia de Nadaı̈, Souphalone Luangsay, Valérie Wittamer, Jean‐Denis Franssen, Maryse Brait, François Huaux, Jean–Yves Springael and Virginie Robert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Olivier De Henau

21 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olivier De Henau United States	9	245	235	166	148	94	22	609
Joanneke C. Kwekkeboom Netherlands	14	237 1.0×	158 0.7×	183 1.1×	103 0.7×	107 1.1×	23	901
Costas Xidakis Greece	13	322 1.3×	121 0.5×	125 0.8×	75 0.5×	62 0.7×	15	650
Ilaria Petrai Italy	10	452 1.8×	115 0.5×	155 0.9×	100 0.7×	74 0.8×	14	784
Adriaan Duijvestijn Netherlands	11	159 0.6×	257 1.1×	187 1.1×	70 0.5×	77 0.8×	14	596
Mara Gallí United States	9	329 1.3×	268 1.1×	273 1.6×	438 3.0×	145 1.5×	12	1.0k
Nam-Ho Choi-Miura Japan	15	200 0.8×	119 0.5×	261 1.6×	183 1.2×	209 2.2×	24	705
Nik Cummings Australia	9	179 0.7×	74 0.3×	189 1.1×	57 0.4×	107 1.1×	12	473
Mitsukazu Gotoh Japan	13	143 0.6×	128 0.5×	212 1.3×	85 0.6×	59 0.6×	58	1.1k
Giorgia Manni Italy	12	85 0.3×	191 0.8×	327 2.0×	117 0.8×	53 0.6×	18	718
Amanda A. Watkins United States	9	248 1.0×	520 2.2×	219 1.3×	232 1.6×	145 1.5×	12	884

Countries citing papers authored by Olivier De Henau

Since Specialization

Citations

This map shows the geographic impact of Olivier De Henau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier De Henau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier De Henau more than expected).

Fields of papers citing papers by Olivier De Henau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier De Henau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier De Henau. The network helps show where Olivier De Henau may publish in the future.

Co-authorship network of co-authors of Olivier De Henau

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier De Henau. A scholar is included among the top collaborators of Olivier De Henau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier De Henau. Olivier De Henau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sanders, Theodore J., Christopher S. Nabel, Margreet Brouwer, et al.. (2025). Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer. Nature Immunology. 26(6). 854–865. 10 indexed citations

Sanders, Theodore J., Christopher S. Nabel, Margreet Brouwer, et al.. (2024). Abstract 734: Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression. Cancer Research. 84(6_Supplement). 734–734. 1 indexed citations

Ma, Stephanie, Iain Welsby, Nicolas Rosewick, et al.. (2023). 74 Abstract withdrawn. SHILAP Revista de lepidopterología. A84–A84. 1 indexed citations

Wald, Noémie, Marjorie Mercier, Iain Welsby, et al.. (2022). Abstract LB189: Pharmacodynamic assessment of a-TIGIT mAb EOS-448 highlights multiple FcγR-mediated mode-of-actions in blood and tumor of patients with advanced solid tumors. Cancer Research. 82(12_Supplement). LB189–LB189. 2 indexed citations

Budhu, Sadna, Rachel Giese, Aditi Gupta, et al.. (2021). Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Reports. 34(2). 108620–108620. 31 indexed citations

Jungels, Christiane, Thi Lien-Anh Nguyên, Olivier De Henau, et al.. (2021). Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers. Cancer Research. 81(13_Supplement). CT118–CT118. 6 indexed citations

Moreau, Philippe, Leona Holmberg, Nathalie Meuleman, et al.. (2021). TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma. Blood. 138(Supplement 1). 2745–2745. 4 indexed citations

Henau, Olivier De, Virginie Robert, Francina Langa, et al.. (2021). The antitumoral effects of chemerin are independent from leukocyte recruitment and mediated by inhibition of neoangiogenesis. Oncotarget. 12(19). 1903–1919. 10 indexed citations

Nguyên, Thi Lien-Anh, Virginie Rabolli, Noémie Wald, et al.. (2020). Abstract 3161: Preparation of aclinical trial with a-TIGIT antagonist antibody EOS884448, which demonstrates potent preclinical activity and safe toxicology profile. Cancer Research. 80(16_Supplement). 3161–3161. 1 indexed citations

10.

Buisseret, Laurence, Sylvie Rottey, Johann S. de Bono, et al.. (2020). Abstract CT152: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers. Cancer Research. 80(16_Supplement). CT152–CT152. 8 indexed citations

11.

Ghosh, Arnab, Lauren Dong, Hong Zhong, et al.. (2019). Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models. Cancer Research. 79(13_Supplement). 4843–4843. 5 indexed citations

12.

Henau, Olivier De, Virginie Robert, Francina Langa, et al.. (2019). Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis. Frontiers in Oncology. 9. 1253–1253. 10 indexed citations

13.

Carleton, Michael, Ming Zhou, Olivier De Henau, et al.. (2018). Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.. Journal of Clinical Oncology. 36(15_suppl). 3025–3025. 5 indexed citations

14.

Henau, Olivier De, Taha Merghoub, David A. Winkler, et al.. (2016). Abstract 554: Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models. Cancer Research. 76(14_Supplement). 554–554. 3 indexed citations

15.

Henau, Olivier De, Virginie Imbault, Virginie Robert, et al.. (2016). Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2. PLoS ONE. 11(10). e0164179–e0164179. 141 indexed citations

16.

Rausch, Matthew, Jeremy H. Tchaicha, Thomas T. Tibbitts, et al.. (2016). Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment. Cancer Immunology Research. 4(11_Supplement). B032–B032. 3 indexed citations

17.

Khalil, Danny N., Sadna Budhu, Billel Gasmi, et al.. (2015). The New Era of Cancer Immunotherapy. Advances in cancer research. 128. 1–68. 34 indexed citations

18.

Bondue, Benjamin, Olivier De Henau, Souphalone Luangsay, et al.. (2012). The Chemerin/ChemR23 System Does Not Affect the Pro-Inflammatory Response of Mouse and Human Macrophages Ex Vivo. PLoS ONE. 7(6). e40043–e40043. 30 indexed citations

19.

Bondue, Benjamin, Olivier Vosters, Patricia de Nadaı̈, et al.. (2011). ChemR23 Dampens Lung Inflammation and Enhances Anti-viral Immunity in a Mouse Model of Acute Viral Pneumonia. PLoS Pathogens. 7(11). e1002358–e1002358. 82 indexed citations

20.

Luangsay, Souphalone, Valérie Wittamer, Benjamin Bondue, et al.. (2009). Mouse ChemR23 Is Expressed in Dendritic Cell Subsets and Macrophages, and Mediates an Anti-Inflammatory Activity of Chemerin in a Lung Disease Model. The Journal of Immunology. 183(10). 6489–6499. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact